Pharm
Foscarnet
search
Foscarnet
, Foscavir, Phosphonoformic Acid
See Also
Cytomegalovirus Retinitis
Cidofovir
Ganciclovir
Valganciclovir
Letermovir
Maribavir
Indications
Cytomegalovirus Retinitis
(
HIV Infection
)
HSV I
nfection (
Acyclovir
-resistant) in
Immunocompromised
patients
Also used for
Acyclovir
-resistant VZV (off-label)
Contraindications
Children (relative contraindication)
May be used if benefit outweighs risk
Mechanism
Synthetic analog of inorganic pyrophosphate
Selectively blocks viral
DNA Polymerase
s at their pyrophosphate binding site, preventing
DNA Replication
Crosses the blood brain barrier
Dosing
Prehydrate before Foscarnet infusion
Normal Saline
750 to 1000 ml for doses 90 to 120 mg/kg
Normal Saline
500 ml for doses 40 to 60 mg/kg
Cytomegalovirus Retinitis
First 2 to 3 weeks
Give 60 mg/kg IV over 1 hour every 8 hours OR
Give 90 mg/kg IV over 1.5 to 2 hours every 12 hours
Next
Give 90 to 120 mg/kg IV over 2 hours daily
HSV I
nfection (
Acyclovir
-resistant)
Give 40 mg/kg IV over 1 hour (no faster than 1 mg/kg/min) every 8 to 12 hours for 2 to 3 weeks
Adverse Effects
Less well tolerated than
Ganciclovir
Nephrotoxicity
Typically resolves on stopping medication, but
Hemodialysis
has been needed for some patients
Anemia
Granulocytopenia
Phlebitis
Nausea
or
Vomiting
Genital Ulcer
s
Ulcers secondary to local urine irritation
Tooth
deposits
Seen in young animals
Electrolyte
abnormalities
Foscarnet contains high
Sodium
concentration (10 meq or 460 mg per mg Foscarnet)
Hypocalcemia
,
Hypomagnesemia
and
Hypokalemia
Avoid rapid infusion (risk of secondary
QTc Prolongation
,
Seizure
s)
Safety
Unknown safety in pregnancy
Unknown safety in
Lactation
Drug Interactions
Nephrotoxic Drug
s
Pentamidine
Hypocalcemia
risk
Resources
Foscarnet Injection Solution (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=90e3da4e-3b1f-428b-99ca-e4bed1c80028
References
(2013) Med Lett Drugs Ther 11(127): 19-30 [PubMed]
(1992) Med Lett Drugs Ther 34(861): 3-4 [PubMed]
Type your search phrase here